Alzheimer’s update 2025: New Frontiers in Diagnosis, Biomarkers and Disease-modifying therapies
-
Register
- User - $30
An update on the current landscape of Alzheimer's diagnosis and treatment, characterized by rapid advances in biomarker-driven diagnosis, the emergence of anti-amyloid and anti-tau therapies, and ongoing challenges in translating clinical trial results into real-world practice, including an update on the integration of novel imaging and plasma biomarkers, and the evolving therapeutic pipeline with monoclonal antibodies and other disease-modifying strategies.
*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.
Credits: 1.0 Contact Hours; 1.0 are Pharmacology
This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid from 1/1/2026 to 12/31/2026 . PAs should only claim credit commensurate with the extent of their participation.
Expiration Date: December 31, 2026
$30
LEARNING OBJECTIVES
After taking part in this educational activity, participants should be better able to:
-Understand the shift toward a biological definition of Alzheimer's disease, using validated biomarkers to diagnose and stage the disease
-Integrating biomarker-based diagnosis, staging and Treatment in to your patient's plan of care
-Discuss and distinguish the patient populations that benefit most from the updated treatment approaches for Alzheimer's disease
Michelle Wade, MSN/Ed, APRN, AGNP-C, ACNPC-AG, FAANP
Lead Hospitalist
Gifford Medical Center
Michelle Wade is a dual-certified Nurse Practitioner specializing in Adult-Gerontological Primary and Acute Care. She is a Fellow of the American Association of Nurse Practitioners (AANP) and a passionate advocate for nurse practitioners and patients at both the state and national levels. Currently, she serves as the President of the Vermont Nurse Practitioners Association and is actively involved in the Conference and Policy Committees. Additionally, Michelle is a board member of the American Nurses Association of Vermont and a graduate of the original AANP Leadership Program. She is currently participating in the AANP Practice Committee.
As an educator, Michelle received the W. Robert Wonkka Advising Award at Vermont Technical College, her alma mater, where she served as a full-time faculty member. She continues to teach as needed across the curriculum at Vermont State University, from the Practical Nursing (PN) program to the Bachelor of Science in Nursing (BSN) program, and enjoys mentoring future nurses. Michelle is a founding member of Omega Mu Sigma and maintains an active membership in Omicron Delta. She founded the college’s chapter of the Alpha Delta Nu honor society and was named Elsevier’s National Educator of the Year during her full-time tenure.
In her clinical role as the lead hospitalist at Gifford Medical Center in Randolph, VT, she provides comprehensive care to a diverse rural population at a critical access hospital. Michelle precepts nurse practitioner students and encourages them to stay and practice in Vermont. She has contributed to an acute care nurse practitioner textbook, reviewed clinical guideline texts, and presented nationally on various topics.
In recognition of her numerous projects and dedication to the profession, Michelle was honored with the inaugural AANP State Award for Outstanding Contribution in 2025. Additionally, in 2018, she received the AANP State Award for Clinical Excellence in Vermont for leading a successful initiative that reduced hospital readmissions from local nursing homes by 70% in one year.
CE/CME INFORMATION
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 1.0 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid from 1/1/2026 to 12/31/2026 . PAs should only claim credit commensurate with the extent of their participation.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURES
Faculty
Contributing faculty, Michelle Wade MSN/Ed, APRN, AGNP-C, ACNPC-AG, FAANP has disclosed no relevant financial relationship.
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity.
Key:
Complete
Next
Failed
Available
Locked
